Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is projected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 14, 2025 at 12:00 AM ET.

Lantern Pharma (NASDAQ:LTRN) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.13. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Stock Down 4.0%

Shares of Lantern Pharma stock opened at $3.82 on Thursday. Lantern Pharma has a twelve month low of $2.55 and a twelve month high of $6.12. The company has a 50-day simple moving average of $4.18 and a two-hundred day simple moving average of $3.87. The stock has a market capitalization of $41.26 million, a price-to-earnings ratio of -2.15 and a beta of 1.57.

Hedge Funds Weigh In On Lantern Pharma

A hedge fund recently bought a new stake in Lantern Pharma stock. XTX Topco Ltd bought a new stake in Lantern Pharma Inc. (NASDAQ:LTRN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 12,624 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned 0.12% of Lantern Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 28.62% of the company’s stock.

Analysts Set New Price Targets

LTRN has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lantern Pharma in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Lantern Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 11th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $25.00.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.